311 related articles for article (PubMed ID: 18200800)
1. A review of nateglinide in the management of patients with type 2 diabetes.
Tentolouris N; Voulgari C; Katsilambros N
Vasc Health Risk Manag; 2007; 3(6):797-807. PubMed ID: 18200800
[TBL] [Abstract][Full Text] [Related]
2. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
Campbell IW
Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
[TBL] [Abstract][Full Text] [Related]
3. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacological properties of nateglinide, rapid-onset/short-duration insulinotropic agent, in the treatment of type 2 diabetes].
Ikenoue T; Kondo N
Nihon Yakurigaku Zasshi; 2000 Sep; 116(3):171-80. PubMed ID: 11031747
[TBL] [Abstract][Full Text] [Related]
5. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.
Hirschberg Y; Karara AH; Pietri AO; McLeod JF
Diabetes Care; 2000 Mar; 23(3):349-53. PubMed ID: 10868864
[TBL] [Abstract][Full Text] [Related]
6. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.
Horton ES; Clinkingbeard C; Gatlin M; Foley J; Mallows S; Shen S
Diabetes Care; 2000 Nov; 23(11):1660-5. PubMed ID: 11092289
[TBL] [Abstract][Full Text] [Related]
7. Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control.
Fonseca V; Grunberger G; Gupta S; Shen S; Foley JE
Diabetes Care; 2003 Jun; 26(6):1685-90. PubMed ID: 12766094
[TBL] [Abstract][Full Text] [Related]
8. [Nateglinide and mitiglinide].
Odawara M
Nihon Rinsho; 2003 Jul; 61(7):1230-7. PubMed ID: 12877090
[TBL] [Abstract][Full Text] [Related]
9. Nateglinide: a new rapid-acting insulinotropic agent.
Hanif W; Kumar S
Expert Opin Pharmacother; 2001 Jun; 2(6):1027-31. PubMed ID: 11585005
[TBL] [Abstract][Full Text] [Related]
10. Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients.
Voytovich MH; Haukereid C; Hjelmesaeth J; Hartmann A; Løvik A; Jenssen T
Clin Transplant; 2007; 21(2):246-51. PubMed ID: 17425753
[TBL] [Abstract][Full Text] [Related]
11. Restoring post-prandial insulin release in type 2 diabetes.
Andrews J
Hosp Med; 2002 Feb; 63(2):95-8. PubMed ID: 11902096
[TBL] [Abstract][Full Text] [Related]
12. [Effects of nateglinide in impaired glucose tolerance subjects].
Hirose T
Nihon Rinsho; 2005 Feb; 63 Suppl 2():438-43. PubMed ID: 15779419
[No Abstract] [Full Text] [Related]
13. The effects of nateglinide following oral glucose load in impaired glucose tolerance subjects: rapid insulin stimulation by nateglinide in IGT subjects.
Hirose T; Mizuno R; Yoshimoto T
Endocr J; 2002 Dec; 49(6):649-52. PubMed ID: 12625415
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent.
McLeod JF
Clin Pharmacokinet; 2004; 43(2):97-120. PubMed ID: 14748619
[TBL] [Abstract][Full Text] [Related]
15. Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population.
Saloranta C; Guitard C; Pecher E; De Pablos-Velasco P; Lahti K; Brunel P; Groop L
Diabetes Care; 2002 Dec; 25(12):2141-6. PubMed ID: 12453951
[TBL] [Abstract][Full Text] [Related]
16. Insulin secretagogues.
Davies MJ
Curr Med Res Opin; 2002; 18 Suppl 1():s22-30. PubMed ID: 12365816
[TBL] [Abstract][Full Text] [Related]
17. Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control.
Pratley RE; Foley JE; Dunning BE
Curr Pharm Des; 2001 Sep; 7(14):1375-97. PubMed ID: 11472274
[TBL] [Abstract][Full Text] [Related]
18. Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.
Derosa G; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Cicero AF
J Clin Pharm Ther; 2009 Feb; 34(1):13-23. PubMed ID: 19125899
[TBL] [Abstract][Full Text] [Related]
19. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.
Hanefeld M; Bouter KP; Dickinson S; Guitard C
Diabetes Care; 2000 Feb; 23(2):202-7. PubMed ID: 10868832
[TBL] [Abstract][Full Text] [Related]
20. Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: assessment using nateglinide, a new insulin secretagogue.
Uchino H; Niwa M; Shimizu T; Nishiyama K; Kawamori R
Endocr J; 2000 Oct; 47(5):639-41. PubMed ID: 11200947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
